Transcript of the Investor''s Conference Call
JUBLINGREA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jubilant Ingrevia reported its highest quarterly revenue in 14 quarters at Rs. 1,179 crore (up 12% YoY) in Q4 FY26, with EBITDA of Rs. 172 crore (up 11% YoY) and PAT of Rs. 86 crore (up 17% YoY). Specialty Chemicals led with Rs. 516 crore revenue maintaining 27% margins for 6 consecutive quarters. The company completed acquisition of Remidex Pharma to expand into Human Nutrition premixes. The Pinnacle Journey strategy is delivering with EBITDA growing 33% over 2 years, portfolio mix improving with 85%+ EBITDA from specialty and nutrition. The CDMO pipeline has grown 3x in 2 years with 100+ opportunities worth Rs. 3,500 crore potential. Management guided for at least 20% EBITDA growth in FY27 with sequential improvement starting Q1. Capex guidance for FY27 is Rs. 400-500 crore. Net debt-to-EBITDA improved to 0.99x.
Strong operational performance with margin recovery and clear growth roadmap positions the company well. The 20%+ EBITDA growth guidance and expanding CDMO pipeline with 20+ confirmed molecules provide visibility into sustained earnings growth. Balance sheet deleveraging (net debt down 11%) gives room for continued investment.